ReviewDiabetic medicine : a journal of the British Diabetic Association2013
Primary and secondary prevention of Type 1 diabetes.
Review in Diabetic medicine : a journal of the British Diabetic Association, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 93 citations in OpenAlex.
- Type 1 diabetes mellitus prevention: present and future.Nature reviews. Endocrinology · 2025Review
- The emerging relationship between mucosal-associated invariant T cell populations and the onset and progression of type 1 diabetes.Frontiers in immunology · 2025Review
- Progression to type 1 diabetes in the DPT-1 and TN07 clinical trials is critically associated with specific residues in HLA-DQA1-B1 heterodimers.Diabetologia · 2024Article
- Common mechanisms underlying diabetic vascular complications: focus on the interaction of metabolic disorders, immuno-inflammation, and endothelial dysfunction.Cell communication and signaling : CCS · 2023Review
- Future number of people with diagnosed type 1 diabetes in Germany until 2040: an analysis based on claims data.BMJ open diabetes research & care · 2023Article
- Temporal trends in the burden of non-communicable diseases in countries with the highest malaria burden, 1990-2019: Evaluating the double burden of non-communicable and communicable diseases in epidemiological transition.Globalization and health · 2022Article
- Safety of the use of gold nanoparticles conjugated with proinsulin peptide and administered by hollow microneedles as an immunotherapy in type 1 diabetes.Immunotherapy advances · 2022Article
- Metabolic and Metabolomic Insights Regarding the Omega-3 PUFAs Intake in Type 1 Diabetes Mellitus.Frontiers in molecular biosciences · 2021Review
- Environmental Determinants of Type 1 Diabetes: From Association to Proving Causality.Frontiers in immunology · 2021Review
- Article
- Dietary EPA Increases Rat Mortality in Diabetes Mellitus, A Phenomenon Which Is Compensated by Green Tea Extract.Antioxidants (Basel, Switzerland) · 2019Article
- Etiology and Pathogenesis of Latent Autoimmune Diabetes in Adults (LADA) Compared to Type 2 Diabetes.Frontiers in physiology · 2019Review
- Beta cell function in type 1 diabetes determined from clinical and fasting biochemical variables.Diabetologia · 2019Review
- Genetics of type 1 diabetes.Pediatric diabetes · 2018Review
- Hope vs hype: where are we in type 1 diabetes?Diabetologia · 2018Review
- Small-Molecule Inhibitors of the CD40-CD40L Costimulatory Protein-Protein Interaction.Journal of medicinal chemistry · 2017Article
- Genetic Risk Scores for Type 1 Diabetes Prediction and Diagnosis.Current diabetes reports · 2017Review
- Type 1 diabetes: where are we in 2017?Translational pediatrics · 2017Review
- Early prediction of autoimmune (type 1) diabetes.Diabetologia · 2017Review
- Nano-curcumin safely prevents streptozotocin-induced inflammation and apoptosis in pancreatic beta cells for effective management of Type 1 diabetes mellitus.British journal of pharmacology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Since type 1 diabetes is an immunologically mediated disease, immune intervention should alter the natural history of the disease. This article reviews prevention studies undertaken either prior to any evidence of autoimmunity (primary prevention) or after the development of islet autoantibodies (secondary prevention). Most immune intervention studies have been conducted in recent-onset type 1 diabetes (tertiary prevention), and these are not reviewed herein. The goal of primary and secondary intervention is to arrest the immune process and thus prevent or delay clinical disease. Primary prevention studies have been conducted in infants with high genetic risk. Interventions tested include several dietary manipulations, including infant formulas free of either cow's milk or of bovine insulin, infant formula supplemented with the omega-3-fatty acid docosahexaenoic acid, delayed introduction of gluten-containing foods, and vitamin D supplementation. Secondary prevention studies have been conducted in both children and adults with diabetes autoantibodies. Interventions tested include nicotinamide, insulin injections, oral insulin, nasal insulin, glutamic acid decarboxylase, and cyclosporine. Underway are secondary prevention studies with teplizumab and with abatacept.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.